文献速递腹部介入MR

钆塞酸增强MRI纵向评估肝细胞癌对立体定向体部放疗的反应:病例系列

Longitudinal assessment of hepatocellular carcinoma response to stereotactic body radiation using gadoxetate-enhanced MRI: A case series.
PubMed 文献 · Eur J Radiol · 2023-09-01

回顾性纳入5例男性(中位年龄61岁)共6个肝细胞癌病灶,SBRT(中位剂量50 Gy)后接受肝移植,用钆塞酸增强MRI纵向评估疗效。病理坏死平均48±42%,多数病灶体积缩小但持续存在动脉期高强化,RECIST1.1、mRECIST与LI-RADS评估结果不一,5/6病灶肝胆期出现周边低信号晕。

要点

  • SBRT后肝细胞癌虽体积缩小,但多数仍持续存在动脉期高强化,病理坏死常不完全。
  • 肝胆期周边低信号晕出现在SBRT后平均3.1个月,5/6病灶可见。
  • RECIST1.1、mRECIST与LI-RADS对SBRT后疗效评估结果不一致,需结合多标准判读。

核心结论

  • 本病例系列显示,接受SBRT并后续肝移植的肝细胞癌多数表现为体积缩小、持续动脉期高强化和病理坏死不完全。

研究设计与样本

  • 回顾性病例系列,纳入5例男性(中位年龄61岁,范围57-64岁)共6个肝细胞癌病灶,SBRT中位剂量50 Gy,随后行肝移植;SBRT前后行钆塞酸增强MRI,由2名观察者共识评估。

关键影像表现/征象

  • 末次移植前MRI显示6个病灶中动脉期高强化4/6、门静脉期廓清3/6、包膜3/6;5/6病灶在肝胆期出现周边低信号晕,SBRT后平均延迟3.1个月出现。

诊断标准与关键数值

  • RECIST1.1评估为部分缓解3例、疾病稳定3例;mRECIST评估为完全缓解2例、部分缓解2例、疾病稳定2例;LI-RADS评估为LR-TR存活4例、LR-TR非存活2例;病理肿瘤坏死平均48±42%(范围10-100%)。

临床应用与阅片要点

  • SBRT后肝细胞癌可在体积缩小的同时持续存在动脉期高强化,RECIST1.1、mRECIST与LI-RADS评估结果可不一致,肝胆期周边低信号晕可于SBRT后平均3.1个月出现。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To describe the longitudinal response in patients with hepatocellular carcinoma (HCC) treated with stereotactic body radiation therapy (SBRT) and who underwent liver transplant (LT) using gadoxetate-enhanced MRI.

METHODS: Five men (median age 61y, range 57-64y) with 6 HCCs treated with SBRT (median dose 50 Gy) who subsequently underwent LT were included in this retrospective study. Patients underwent gadoxetate-enhanced MRI before and after SBRT over a period of 3-18 months. Response was assessed using RECIST1.1, mRECIST, LI-RADS and image subtraction, by 2 observers in consensus. Percentage of pathologic tumor necrosis was evaluated.

RESULTS: LT was performed 278 days (IQR, 148-418d) after completion of SBRT and 48d after the last MRI. Histopathology demonstrated tumor necrosis of 48 ± 42% (range, 10-100%). Mean tumor size at baseline and last post-treatment MRIs pre-LT were 2.6 ± 0.8 cm and 2.4 ± 0.9 cm. Enhancing tumor component size at baseline MRI and last post-treatment MRI pre-LT were 1.6 ± 0.8 cm and 0.9 ± 1.0 cm. Responses assessed at the last LRI pre-LT were: partial response (PR, n = 3), stable disease (SD, n = 3) using RECIST1.1; complete response (CR, n = 2), partial response (PR, n = 2), stable disease (SD, n = 2) using mRECIST; and LR-TR viable (n = 4), LR-TR non-viable (n = 2) using LI-RADS. At the last MRI pre-LT, per-lesion features of arterial phase hyperenhancement (APHE, 4/6), portal venous washout (3/6) and capsule (3/6) were observed. 5/6 lesions displayed a hypointense perilesional halo on hepatobiliary phase with a mean delay of 3.1 months post-SBRT.

CONCLUSIONS: This case-series showed decreased size, persistent APHE, and incomplete pathologic necrosis in most HCCs treated with SBRT undergoing transplant.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Sharma HK, Kyriakakos C, Jabbour TE, et al. Longitudinal assessment of hepatocellular carcinoma response to stereotactic body radiation using gadoxetate-enhanced MRI: A case series. Eur J Radiol. 2023. PMID: 37688918. doi:10.1016/j.ejrad.2023.111077

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。